Agosti R, Duke R K, Chrubasik J E, Chrubasik S
Headache Center Hirslanden, Münchhaldenstr. 33, 8008 Zürich, Switzerland.
Phytomedicine. 2006 Nov;13(9-10):743-6. doi: 10.1016/j.phymed.2006.02.008. Epub 2006 Sep 20.
The objective of this review was to evaluate the strength of evidence of effectiveness for Petasites hybridus in the prophylaxis of migraine. Several databases and other sources were searched to identify randomised-controlled trials investigating P. hybridus preparations. Two trials totalling 293 patients (60 and 233 patients) were included in this review. Both trials investigated the proprietary Petasites root extract Petadolex. The trials were described in narrative way, taking into consideration methodological quality scores. Pooling of data was not carried out due to the heterogeneity of the results. The extract at higher dose (150 mg) showed a greater decreased frequency of migraine attacks and a greater number of responders (improvement>50%) after treatment over 3-4 months than the extract at lower dose (100 mg) and placebo. Moderate evidence of effectiveness is, thus, available for a higher than the recommended dose of the proprietary Petasites root extract Petadolex in the prophylaxis of migraine. Further rigorous studies are required to confirm effectiveness and safety in long-term use before treatment with Petasites root extract can be recommended as an alternative option in the treatment schedule for the prophylaxis of migraine.
本综述的目的是评估蜂斗菜在预防偏头痛方面有效性的证据强度。检索了多个数据库及其他来源，以确定调查蜂斗菜制剂的随机对照试验。本综述纳入了两项试验，共计293名患者（分别为60名和233名患者）。两项试验均研究了专利蜂斗菜根提取物Petadolex。考虑到方法学质量评分，以叙述方式描述了试验。由于结果的异质性，未进行数据合并。与低剂量（100毫克）提取物和安慰剂相比，高剂量（150毫克）提取物在3 - 4个月的治疗后显示偏头痛发作频率降低幅度更大，且有更多的反应者（改善>50%）。因此，有中等强度的证据表明，专利蜂斗菜根提取物Petadolex高于推荐剂量时在预防偏头痛方面有效。在将蜂斗菜根提取物推荐作为偏头痛预防治疗方案中的替代选择之前，还需要进一步严格的研究来证实其长期使用的有效性和安全性。
